To assess the benefits and harms of 3,4-DAP for autoimmune MG, transient NMG and the CMS on 1) endurance, and 2) muscle strength, quality of life and Myasthenia Gravis Foundation of America (MGFA) status.
This is a protocol.
3,4-Diaminopyridine for myasthenia gravis
You may also be interested in:
- Ephedrine treatment for myasthenia gravis, neonatal myasthenia and congenital myasthenic syndromes
- A review of the use of drugs that suppress the immune system (immunosuppressants) in myasthenia gravis.
- Corticosteroids for myasthenia gravis
- Plasma exchange for generalised myasthenia gravis
- Surgical removal of the thymus for myasthenia gravis that is not caused by a tumour of the thymus